Non-Invasive and Radiation-Free Diagnostic Identifies Early-Stage Lung Cancer Across All Subtypes

Lung cancer remains the leading cause of cancer-related deaths, with nearly 125,000 deaths and 227,000 new cases estimated in the U.S. for 2025. Despite evidence showing that early detection significantly improves five-year survival rates, only 2% to 6% of at-risk individuals undergo recommended low-dose CT scans annually. Now, a highly sensitive, radiation-free, non-invasive blood test can detect early lung cancer signs, even in asymptomatic patients across all subtypes.

Hawkeye Bio’s (Torrance, CA, USA) LEAP (Lung Enzymatic Activity Profiling) test is designed to detect cancer signatures using a simple blood draw that is safe and non-invasive. The test poses no radiation risk and is 100% patient-safe. LEAP employs patented biosensor technology to analyze 19 lung cancer biomarkers, delivering fast, highly accurate results with excellent sensitivity and specificity.

Image: The patented biosensor measures enzymatic activity associated with inflammatory disease (Photo courtesy of Hawkeye Bio)

Unlike conventional methods, Hawkeye’s biosensors measure enzyme activity rather than their quantity, allowing the detection of subtle biological changes associated with chronic inflammatory diseases like cancer and autoimmunity. This technology works with non-invasive samples such as blood, saliva, urine, or even exhaled breath. The LEAP test achieves high sensitivity across all lung cancer subtypes, ensuring early detection even in high-risk individuals.

With LEAP, people at risk for lung cancer can be identified cost-effectively and confirmed using LDCT, enabling doctors to intervene before metastasis occurs. By using serum from a standard blood draw, LEAP also complements current low-dose CT and liquid biopsy approaches, reducing unnecessary biopsies and providing safer, more efficient diagnostic workflows.

Related Links:
Hawkeye Bio